and polymorphisms and clopidogrel resistance in ischemic heart disease patients.

Polymorphisms in and genes are thought to be involved in clopidogrel high on treatment reactivity in ischemic heart disease (IHD) patients. A total of 240 patients with IHD were screened for loss-of-function alleles (LOF; *2, *3) and Q192R. Patients were classified as responders and nonresponders to clopidogrel based upon platelet aggregation studies.